Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials (Q34157981)

31 July 2017

1 reference

title

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials (English)

1 reference

31 July 2017

R Collins

1

1 reference

PubMed ID

11211013

31 July 2017

S MacMahon

series ordinal

2

1 reference

PubMed ID

11211013

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

31 July 2017

1 reference

31 July 2017

357

1 reference

31 July 2017

373-380

1 reference

31 July 2017

9253

1 reference

Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

The role of randomization in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Amniotomy or oxytocin for induction of labor. Re-analysis of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Failure of randomisation by "sealed" envelope

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Randomized trials or observational tribulations?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Adjusting for non-compliance and contamination in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Discussion Sections in Reports of Controlled Trials Published in General Medical Journals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Why sources of heterogeneity in meta-analysis should be investigated

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Is aspirin safe for patients with heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

A Meta-analysis of Low-Dose Aspirin for the Prevention of Pregnancy-Induced Hypertensive Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Trial of calcium to prevent preeclampsia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

The effects of nimodipine on the clinical course of patients with acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Vitamin E supplementation and cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

The Extracranial-Intracranial Bypass Study. A report of the committee appointed by the American Association of Neurological Surgeons to examine the study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Are the results of the extracranial-intracranial bypass trial generalizable?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Estimation issues in clinical trials and overviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Thrombolytic therapy in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Thrombolytic therapy in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Can overall results of clinical trials be applied to all patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Variation in use of adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Methods in health service research. An introduction to bayesian methods in health technology assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Randomised trial of oral aspirin for chronic venous leg ulcers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903651-5

7 January 2021

10.1016/S0140-6736(00)03651-5

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11211013